STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #188 by analyst upside · 2026-06-27
UNCY
Unicycive Therapeutics, Inc.
Healthcare · Market Cap $195M · P/E 0x
ANALYST PRICE TARGET
+479.2%
implied upside to consensus target
Current Price $7.13
Consensus Target $41.3
Bull Target $90.0
Bear Target $18.0
Analysts Covering 10
ANALYST CONSENSUS — BUY
Strong Buy
2
Buy
8
Hold
0
Sell
0
52-Week Low $3.71
52-Week High $8.74
YTD Return +22.9%
FUNDAMENTALS
Market Cap $195M
P/E Ratio (TTM) N/A
Forward P/E 1.2x
EPS (TTM) $-1.96
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $3.71
52-Week High $8.74
Current Price $7.13
Bear Target $18.0
Bull Target $90.0
● Now $7.13 ● Target $41.3
TRADING DATA
Avg Volume 766K
YTD Return +22.9%
Analyst Count 10
Consensus Buy
Upside to Target +479.2%
Last Updated 2026-06-27

ANALYST SUMMARY

Unicycive Therapeutics, Inc. (UNCY) is currently trading at $7.13 with a Wall Street consensus price target of $41.3, implying potential upside of 479.2% over the next 12 months. 10 analysts currently cover UNCY, with a consensus rating of Buy — 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $90.0, while the most cautious has a target of $18.0.

UNCY operates in the Healthcare sector with a market capitalisation of $195M. The stock is up 22.9% year-to-date and is currently trading near the upper end of its 52-week range of $3.71 – $8.74.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for UNCY, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Benchmark — Reiterated
Speculative Buy → Speculative Buy 2026-06-02 Building track record
Guggenheim — Reiterated
Buy → Buy 2026-05-13 62% win rate (8 calls)
Benchmark — Reiterated
Speculative Buy → Speculative Buy 2026-04-06 Building track record
Guggenheim — Reiterated
Buy → Buy 2026-04-02 62% win rate (8 calls)
HC Wainwright & Co. — Reiterated
Buy → Buy 2025-10-29 31% win rate (48 calls)
Benchmark — Reiterated
Speculative Buy → Speculative Buy 2025-09-15 Building track record
Guggenheim ● Initiated
Buy 2025-04-21 62% win rate (8 calls)
HC Wainwright & Co. reit
Buy → Buy 2025-04-11 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
45
out of 100
Coverage depth
18/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →